Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 18;10:550185. doi: 10.3389/fonc.2020.550185

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Gerratana, Basile, Franzoni, Allegri, Viotto, Corvaja, Bortot, Bertoli, Buriolla, Targato, Da Ros, Russo, Bonotto, Belletti, Baldassarre, Damante and Puglisi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Variation of promA (purple) and promB (blue) between BL and EV1 (A,B) and impact on PFS (C,D) and OS (E,F) of a ≥2-fold increase in promA and promB. Subgroup analysis of the impact on PFS of a ≥2-fold increase in promB (G). A numerical increase in promA was observed after normalization to the baseline levels. For two cases, an 18- and 15-fold increase in promB was observed (B) and were, therefore, out of scale (B). A ≥2-fold increase in promA was not associated with PFS or OS (C,E), while a doubling in promB resulted in a significantly worse prognosis both on PFS and OS (D,F). Notably, subgroup analysis showed a consistent impact on PFS across different ET backbones and according to ESR1 and PIK3CA mutational status.